NCT06072612Phase 3Recruiting

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Study sponsor: BriaCell Therapeutics Corporation

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-12Estimated

Enrollment · participants404Estimated

Source updated2026-09-02Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-01-06 · 1 field changed

Primary completion date changed

− Before

~~Jan 2026~~

+ After

Dec 2027

Check registry source

Study details

Conditions studied

Breast Cancer; Metastatic Breast Cancer; Breast Neoplasm; Breast Cancer Metastatic; End Stage Cancer

Treatments or interventions studied

SV-BR-1-GMBiologicalAlso known as Part of the Bria-IMT regimen
CyclophosphamideDrug
Interferon infiltration of the inoculation siteDrug
RetifanlimabDrug
Treatment of Physician's ChoiceDrug

Primary outcomes · main study measures

measure: Overall Survival; description: To evaluate the effect of the Bria-IMT regimen in combination with Check Point Inhibitor (CPI) on overall survival (OS) compared to treatment of physician's choice (TPC) chemotherapy in patients with metastatic breast cancer with no approved alternative therapies available as per the Inclusion criteria.; timeFrame: Up to 60 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history